Download Image
    
Share
  
Post
MAS825 for COVID-19
1 study with 138 patients
Hospital Icon Control
Hospital Icon MAS825 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 MAS825 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -16% Mortality -16% RCTs -16% Late -16% FavorsMAS825 Favorscontrol
Jun 20
2023
 Hakim et al., Clinical and Experimental Immunology, doi:10.1093/cei/uxad065 Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function
16% higher mortality (p=0.59) and 7% worse recovery (p=0.7). RCT 138 hospitalized COVID-19 patients with pneumonia showing no significant difference in mortality or APACHE II scores with MAS825 (anti-IL-1β/IL-18 monoclonal antibody) compared to placebo.